Shares of Lion Biotechnologies Inc. (NASDAQ:LBIO) climbed 43.4 percent to $8.65 on Friday as the cancer immunotherapy developer announced the appointment of new President and CEO Maria Fardis and a $100 million equity financing led by Quogue Capital, Orbimed Advisors, Frazier Healthcare Partners and Broadfin Capital.
